Last A$0.50 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 12:16 AM 04/30/14 All times are local (Market data is delayed by at least 15 minutes).

healthlinx ltd (HTX) Snapshot

Open
--
Previous Close
A$0.50
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
A$-0.11
Shares Outstanding
27.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HEALTHLINX LTD (HTX)

Related News

No related news articles were found.

healthlinx ltd (HTX) Related Businessweek News

No Related Businessweek News Found

healthlinx ltd (HTX) Details

HealthLinx Limited engages in the identification and development of novel, non-invasive, serum, and plasma based multi marker diagnostics. It primarily develops Ovplex, an ovarian cancer diagnostic; and IgY. The company is based in Melbourne, Australia.

healthlinx ltd (HTX) Top Compensated Officers

Chairman and Secretary
Total Annual Compensation: --
General Manager of Australian Operations
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

healthlinx ltd (HTX) Key Developments

HealthLinx Limited, Annual General Meeting, Jan 12, 2015

HealthLinx Limited, Annual General Meeting, Jan 12, 2015., at 11:00 AUS Eastern Standard Time. Location: The offices of Quinert Rodda & Associates Pty Ltd, Suite 1. Agenda: To consider the Annual Financial Statements of the Company for the financial year ended 30 June 2014 together with the declaration of the Directors, the Directors' Report, the Remuneration Report and the Auditor's Report; to consider the adoption of remuneration report; to consider the election of director ­Mr. Timothy Chapman; to consider the re-election of director ­Mr. Michael Quinert; to consider the approval for disposal of main undertaking; to consider the approval of placement facility; and to consider the ratification of prior issue.

Healthlinx Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2014

HealthLinx Limited reported audited consolidated earnings results for the year ended June 30, 2014. For the period, the company reported revenue of AUD 7,192 against AUD 34,721 for the same period last year. Total revenue and other income was AUD 64,734 against AUD 50,493 for the same period last year. Loss before income tax was AUD 363,677 against AUD 4,365,297 for the same period last year. Net loss was AUD 270,682 or 0.0219 cents per basic and diluted share against AUD 3,952,613 or 0.006 cents per basic and diluted share for the same period last year. Net cash used in operating activities was AUD 353,525 against AUD 661,153 for the same period last year.

HealthLinx Limited Auditor Raises 'Going Concern' Doubt

HealthLinx Limited filed its Annual on Nov 19, 2014 for the period ending Jun 30, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HTX:AU A$0.50 AUD 0.00

HTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HTX.
View Industry Companies
 

Industry Analysis

HTX

Industry Average

Valuation HTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,619.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,595.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEALTHLINX LTD, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.